Evolving Strategies for Therapeutically Targeting Cancer Stem Cells

摘要: Cancer is a multifactor and multistep process that affected intrinsically by the genetic epigenetic makeup of tumor cells extrinsically host microenvironment immune system. A key component cancer involves unique subpopulation highly malignant cancerous referred to as stem (CSCs). CSCs are positioned at apex hierarchy with an ability both self-renew also generate non-CSC/differentiated progeny, which contribute majority mass. undergo functional changes show plasticity stimulated specific microenvironmental cues interactions in niche, complexity heterogeneity CSC population. The prognostic value clinic evident since there many examples serve markers for poor patient prognosis. innately resistant standard therapies they display anoikis resistance, evasion, dormancy, field cancerization, may result metastasis relapse. Many academic laboratories biotechnology companies currently focusing on strategies target CSCs. Combination therapies, modifiers, stemness inhibitors, surface marker-based immunotherapy-based CSC-targeting drugs undergoing clinical trials. Potential new targets/strategies CSC-targeted therapy include MDA-9/Syntenin (SDCBP), Patched (PTCH), targets, noncoding RNAs, differentiation induction. Defining ways targeting destroying holds potential impact significantly therapy, including prevention recurrence.